Against pragmatism: On efficacy, effectiveness and the real world

Trials

Volumn 10, Issue , 2009, Pages

  Kent, David M ^a   Kitsios, Georgios ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL STUDY; EVIDENCE BASED MEDICINE; PATIENT CARE; CLINICAL TRIAL; DECISION MAKING; EDITORIAL; HEALTH CARE POLICY; HUMAN; METHODOLOGY; STANDARD;

CLINICAL TRIALS AS TOPIC; DECISION MAKING; EVIDENCE-BASED MEDICINE; HEALTH POLICY; HUMANS;

EID: 68349096138     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-10-48     Document Type: Article

References (12)

1. Avorn J Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs NY: Knopf 2004.
2. Treweek S Zwarenstein M Making trials matter: Pragmatic and explanatory trials and the problem of applicability Trials 2009, 10:37. (3 June 2009) 2700087 19493350 10.1186/1745-6215-10-37
3. Thorpe KE Zwarenstein M Oxman AD Treweek S Furberg CD Altman DG Tunis S Bergel E Harvey I Magid DJ Chalkidou K A pragmatic-explanatory continuum indicator summary (PRECIS): A tool to help trial designers CMAJ 2009, 180:E47-E57. 2679824 19372436
4. Tunis SR Stryer DB Clancy CM Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy JAMA 2003, 290:1624-1632. 10.1001/jama.290.12.1624 14506122
5. US Food and Drug Administration Guidance for Institutional Review Boards and Clinical Investigators 1998 Update 2009. 7-1-2009
6. Rothwell PM Can overall results of clinical trials be applied to all patients? Lancet 1995, 345:1616-1619. 10.1016/S0140-6736(95)90120-5 7783541
7. Kent DM Hayward RA Limitations of applying summary results of clinical trials to individual patients: The need for risk stratification JAMA 2007, 298:1209-1212. 10.1001/jama.298.10.1209 17848656
8. Hayward RA Kent DM Vijan S Hofer TP Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis BMC Med Res Methodol 2006, 6:18. 1523355 16613605 10.1186/ 1471-2288-6-18
9. Rothwell PM Mehta Z Howard SC Gutnikov SA Warlow CP Treating individuals 3: From subgroups to indiGiduals: general principles and the example of carotid endarterectomy Lancet 2005, 365:256-265. 15652609
10. Rothwell PM Warlow CP Prediction of benefit from carotid endarterectomy in individual patients: A risk-modelling study. European Carotid Surgery Trialists' Collaborative Group Lancet 1999, 353:2105-2110. 10.1016/ S0140-6736(98)11415-0 10382694
11. Kent DM Alsheikh-Ali A Hayward RA Competing risk and heterogeneity of treatment effect in clinical trials Trials 2008, 9:30. 2423182 18498644 10.1186/1745-6215-9-30
12. Bloom BR The highest attainable standard: Ethical issues in AIDS vaccines Science 1998, 279:186-188. 10.1126/science.279.5348.186 9446225